These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 31850909)

  • 1. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
    Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
    Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal Cell Carcinoma With Fibromyomatous Stroma-The Whole Story.
    Shah RB
    Adv Anat Pathol; 2022 May; 29(3):168-177. PubMed ID: 35249990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm.
    Chen YB; Mirsadraei L; Jayakumaran G; Al-Ahmadie HA; Fine SW; Gopalan A; Sirintrapun SJ; Tickoo SK; Reuter VE
    Am J Surg Pathol; 2019 Jan; 43(1):121-131. PubMed ID: 30303819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal Cell Carcinoma in Tuberous Sclerosis Complex.
    Henske EP; Cornejo KM; Wu CL
    Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34680979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TSC/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases.
    Tjota MY; Sharma A; Wanjari P; Fitzpatrick C; Segal J; Antic T
    Hum Pathol; 2023 Apr; 134():124-133. PubMed ID: 36592877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous: Clinicopathologic and Molecular Study.
    Tjota M; Chen H; Parilla M; Wanjari P; Segal J; Antic T
    Am J Surg Pathol; 2020 Jul; 44(7):943-954. PubMed ID: 32091432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biallelic ELOC-Inactivated Renal Cell Carcinoma: Molecular Features Supporting Classification as a Distinct Entity.
    Batavia AA; Rutishauser D; Sobottka B; Schraml P; Beerenwinkel N; Moch H
    Mod Pathol; 2023 Aug; 36(8):100194. PubMed ID: 37088333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others.
    Li H; Argani P; Halper-Stromberg E; Lotan TL; Merino MJ; Reuter VE; Matoso A
    Am J Surg Pathol; 2023 Nov; 47(11):1267-1273. PubMed ID: 37661807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum.
    Palsgrove DN; Li Y; Pratilas CA; Lin MT; Pallavajjalla A; Gocke C; De Marzo AM; Matoso A; Netto GJ; Epstein JI; Argani P
    Am J Surg Pathol; 2018 Sep; 42(9):1166-1181. PubMed ID: 29975249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study.
    Tjota MY; Wanjari P; Segal J; Antic T
    Hum Pathol; 2021 Sep; 115():84-95. PubMed ID: 33352195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-grade oncocytic tumor of kidney harboring TSC/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity.
    Zhang HZ; Xia QY; Wang SY; Shi MJ; Wang SY
    Virchows Arch; 2022 May; 480(5):999-1008. PubMed ID: 35099634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of clinicopathological and molecular features of ELOC(TCEB1)-mutant renal cell carcinoma.
    Wang Y; Zhao P; Wang L; Wang J; Ji X; Li Y; Shi H; Li Y; Zhang W; Jiang Y
    Pathol Res Pract; 2022 Jul; 235():153960. PubMed ID: 35653922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic and Molecular Characterization of Xanthomatous Giant Cell Renal Cell Carcinomas: Further Support for a Close Morphologic Spectrum to Eosinophilic Solid and Cystic Renal Cell Carcinomas.
    Xu Y; Zhang X; Xia Q; Zhou Y; Wang X; Fang R; Wang Y; Tong Q; Chen J; Shi J; Fu Y; Rao Q
    Am J Surg Pathol; 2024 Jun; 48(6):662-670. PubMed ID: 38595297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are Sporadic Eosinophilic Solid and Cystic Renal Cell Carcinomas Characterized by Somatic Tuberous Sclerosis Gene Mutations?
    Parilla M; Kadri S; Patil SA; Ritterhouse L; Segal J; Henriksen KJ; Antic T
    Am J Surg Pathol; 2018 Jul; 42(7):911-917. PubMed ID: 29668487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutated ASXL1 upregulates mTOR expression in renal cell carcinoma with fibromyomatous stroma.
    Liu Y; Zhou L; Xu H; Gu Y; Dong L; Yang X; Wang C
    Virchows Arch; 2024 Aug; 485(2):379-382. PubMed ID: 38102390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases.
    Farcaş M; Gatalica Z; Trpkov K; Swensen J; Zhou M; Alaghehbandan R; Williamson SR; Magi-Galluzzi C; Gill AJ; Tretiakova M; Lopez JI; Montiel DP; Sperga M; Comperat E; Brimo F; Yilmaz A; Siadat F; Sangoi A; Gao Y; Ptákova N; Kuthi L; Pivovarcikova K; Rogala J; Agaimy A; Hartmann A; Fraune C; Rychly B; Hurnik P; Durcansky D; Bonert M; Gakis G; Michal M; Hora M; Hes O
    Mod Pathol; 2022 Mar; 35(3):344-351. PubMed ID: 34521993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma.
    Mehra R; Vats P; Cao X; Su F; Lee ND; Lonigro R; Premkumar K; Trpkov K; McKenney JK; Dhanasekaran SM; Chinnaiyan AM
    Eur Urol; 2018 Oct; 74(4):483-486. PubMed ID: 29941307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eosinophilic, Solid, and Cystic Renal Cell Carcinoma: Clinicopathologic Study of 16 Unique, Sporadic Neoplasms Occurring in Women.
    Trpkov K; Hes O; Bonert M; Lopez JI; Bonsib SM; Nesi G; Comperat E; Sibony M; Berney DM; Martinek P; Bulimbasic S; Suster S; Sangoi A; Yilmaz A; Higgins JP; Zhou M; Gill AJ; Przybycin CG; Magi-Galluzzi C; McKenney JK
    Am J Surg Pathol; 2016 Jan; 40(1):60-71. PubMed ID: 26414221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.
    Roldan-Romero JM; Santos M; Lanillos J; Caleiras E; Anguera G; Maroto P; García-Donas J; de Velasco G; Martinez-Montes ÁM; Calsina B; Monteagudo M; Letón R; Leandro-García LJ; Montero-Conde C; Cascón A; Robledo M; Rodriguez-Antona C
    Mod Pathol; 2020 Dec; 33(12):2580-2590. PubMed ID: 32616874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney.
    Aydin H; Chen L; Cheng L; Vaziri S; He H; Ganapathi R; Delahunt B; Magi-Galluzzi C; Zhou M
    Am J Surg Pathol; 2010 Nov; 34(11):1608-21. PubMed ID: 20924276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.